Han Eunkyung, Kim Jiyoon, Jung Min Jung, Chin Susie, Lee Ji-Hye, Won Kyu Yeoun, Moon Ahrim
Department of Pathology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine Bucheon, Republic of Korea.
Department of Pathology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine Cheonan, Republic of Korea.
Int J Clin Exp Pathol. 2021 Jan 1;14(1):116-125. eCollection 2021.
Renal cell carcinoma (RCC) accounts for approximately 90% of all renal malignancy. Because a rich vasculature is an outstanding feature of RCC, information on the blood vessels of RCC might explain its tumor characteristics. Several researchers have noted the effects of tumor vessels on the clinicopathologic characteristics and prognosis of tumors; however, a clear association has not been established. We hypothesized that the immaturity of the neovasculature may be an important clinicopathologic characteristic forprognosis of RCC patients. ERG and nestin are new vascular markers that regulate vascular homeostasis and angiogenesis. Therefore, in the present study, we investigated how ERG and nestin were expressed with respect to tumor characteristics.
IHC staining for ERG, nestin, CD31, and CD34 was performed for 217 renal tumors, including clear-cell RCC (ccRCC; n = 184), papillary RCC (pRCC; n = 14), chromophobe RCC (chRCC; n = 14), and oncocytoma (n = 5).
Vascular endothelial cells from normal kidney consistently showed strong nuclear expression of ERG and nestin. Conversely, a loss of ERG and nestin expression was observed in endothelial cells of some tumor blood vessels, which was associated with tumor progression. In particular, the loss of ERG expression was significantly associated with progression-free survival and overall survival (univariate analyses: = 0.027 and = 0.004, respectively; multivariate analyses: = 0.030 and = 0.046, respectively).
A loss of ERG and nestin expression is associated with tumor progression, and loss of ERG is a powerful prognostic marker for ccRCC.
肾细胞癌(RCC)约占所有肾脏恶性肿瘤的90%。由于丰富的血管系统是RCC的一个突出特征,关于RCC血管的信息可能解释其肿瘤特征。一些研究人员已经注意到肿瘤血管对肿瘤临床病理特征和预后的影响;然而,尚未建立明确的关联。我们假设新生血管的不成熟可能是RCC患者预后的一个重要临床病理特征。ERG和巢蛋白是调节血管稳态和血管生成的新血管标志物。因此,在本研究中,我们调查了ERG和巢蛋白相对于肿瘤特征的表达情况。
对217例肾肿瘤进行ERG、巢蛋白、CD31和CD34的免疫组化染色,包括透明细胞RCC(ccRCC;n = 184)、乳头状RCC(pRCC;n = 14)、嫌色细胞RCC(chRCC;n = 14)和嗜酸细胞瘤(n = 5)。
正常肾脏的血管内皮细胞始终显示出ERG和巢蛋白的强核表达。相反,在一些肿瘤血管的内皮细胞中观察到ERG和巢蛋白表达缺失,这与肿瘤进展相关。特别是,ERG表达缺失与无进展生存期和总生存期显著相关(单因素分析:分别为 = 0.027和 = 0.004;多因素分析:分别为 = 0.030和 = 0.046)。
ERG和巢蛋白表达缺失与肿瘤进展相关,ERG缺失是ccRCC的一个有力预后标志物。